. 2021 Apr 27;11:672747. doi: 10.3389/fonc.2021.672747

Table 2.

Benefits and limitations for using the MPE to develop T cell biomarkers for ICB therapy response.

Benefits	Limitations
• MPE-derived T cells are similar in phenotype to tumor infiltrating lymphocytes (TILs) • Ability to develop a dynamic biomarker as multiple fluid drainage due to MPE recurrence is common for thoracic cancer patients • Opportunity to perform high-throughput sequencing technologies i.e. RNAseq and TCRseq on the anti-tumor immune response where tumor biopsies are limited, particularly in malignant mesothelioma	• Fluid volume, cellularity, number and timing of drainage events varies between patients • External factors such as lung diseases, inflammation and infection could alter MPE-derived T cells • Improved MPE treatment regimens that cause pleural space destruction to prevent fluid recurrence.

Benefits

Limitations

• MPE-derived T cells are similar in phenotype to tumor infiltrating lymphocytes (TILs)
• Ability to develop a dynamic biomarker as multiple fluid drainage due to MPE recurrence is common for thoracic cancer patients
• Opportunity to perform high-throughput sequencing technologies i.e. RNAseq and TCRseq on the anti-tumor immune response where tumor biopsies are limited, particularly in malignant mesothelioma

• Fluid volume, cellularity, number and timing of drainage events varies between patients
• External factors such as lung diseases, inflammation and infection could alter MPE-derived T cells
• Improved MPE treatment regimens that cause pleural space destruction to prevent fluid recurrence.